• CSS Log In
  • Language
  • Transcriptome Sequencing
  • Eukaryote
  • mRNA Sequencing
  • Non-coding RNA Sequencing
  • Long non-coding RNA Sequencing
  • Small RNA Sequencing
  • Circular RNA Sequencing
  • Whole Transcriptome Sequencing
  • Isoform Sequencing (Full-length Transcript Sequencing)
  • Prokaryote
  • Prokaryotic RNA Sequencing
  • Metatranscriptome Sequencing
  • Epigenomics
  • Whole Genome Bisulfite Sequencing (Gene Methylation)
  • Reduced Representation Bisulfite Sequencing (RRBS-Gene Methylation)
  • ChIP-Seq
  • RIP-Seq
  • Metagenomics
  • 16S/18S/ITS Amplicon Metagenomic Sequencing
  • Shotgun Metagenomic Sequencing
  • Pre-made Library Sequencing
  • Pre-made Library Sequencing
  • Clinical Diagnostics
  • Clinical Whole Exome Sequencing (CLIA/CAP)
  • Clinical Panels
  • Genetic Testing
  • Oncology
  • NovoPM™ 2.0
  • NovoFocus™ NSCLC 2.0
  • NovoFocus™ CRC 2.0
  • NovoFocus™ PARPi CDx 1.0
  • NovoFocus™ CR
  • Cancer Immunotherapy Biomarkers
  • Patient's Case Study
  • Biopharma Services
  • Discovery and Pre Clinical
  • Whole Genome Sequencing
  • Whole Exome Sequencing
  • RNA-Seq
  • FFPE RNA-seq
  • Small RNA Sequencing
  • Pacbio Sequencing (DNA)
  • Pacbio Sequencing (RNA)
  • Pre-made Library Sequencing
  • Translational and Clinical
  • NovoPM™ 2.0
  • NovoNeoantigen™ 2.0
  • Star Allele Analysis
  • Tumor Microenvironment Analysis
  • Companion Diagnostics
  • Service Support
  • Service Workflow
  • Sample Preparation Guide
  • Sample Requirements
  • Quality Management
  • Data Analysis
  • FAQs​​
  • Technology
  • Overview
  • Platform
  • Certification
  • Intelligent Delivery Platform
  • Resources
  • Publications
  • Downloads
  • Brochure/Magazine
  • Webinars
  • About
  • About Us
  • Major Milestones
  • Careers
  • News & Events
  • Partnership
  • Contact Us
  • De novo Sequencing
  • Animal & Plant De novo Sequencing
  • Microbial De novo Sequencing
  • Transcriptome Sequencing

  • Whole Transcriptome Sequencing
  • Isoform Sequencing (Full-length Transcript Sequencing)
  • Prokaryote
  • Prokaryotic RNA Sequencing
  • Metatranscriptome Sequencing
  • Epigenomics

    Metagenomics

    Pre-made Library Sequencing

  • Overview
  • Platform
  • Certification
  • Intelligent Delivery Platform
  • Publications
  • Downloads
  • Brochure/Magazine
  • Webinars
  • About Us
  • Major Milestones
  • Careers
  • News & Events
  • Partnership
  • Tell us about your project
    Contact us to discuss how we can help you achieve your research goals
    Services

    Whole Genome Bisulfite Sequencing (Gene Methylation)

    Overview

    DNA methylation at the C5 position of cytosine plays a crucial role in gene expression and chromatin remodeling. Perturbations in methylation patterns are implicated in tumorigenesis, neurodegenerative diseases and neurological disorders. Therefore, methylome analysis is an increasingly valuable research tool with a range of applications, including studies on gene regulation, cell differentiation, embryogenesis, aging, occurrence and development of disease, phenotypic diversity and evolution in plants and animals. Novogene provides whole genome sequencing of bisulfite-converted DNA as an effective method to identify individually methylated cytosines on a genome-wide scale. The deep reach of the methylome is vital to understanding gene expression and other processes that are subject to epigenetic regulation.

    Service Specifications

    Applications

    Applications range from transcriptional regulation to developmental pathways to disease mechanisms and beyond.
    For medical research:

  • Pathological mechanism
  • Tumor-subtypes classification
  • Molecular markers
  • Human evolution
  • Drug target
  • For agricultural research:

  • Development
  • Adaptability
  • Agronomic traits
  • Advantages

  • Extensive experience: Hundreds of projects successfully completed by a bioinformatics analysis team composed entirely of Ph.D. scientists.
  • Unsurpassed data quality: We guarantee that ≥ 80% of bases have a sequencing quality score ≥ Q30, exceeding Illumina’s official guarantee of ≥ 75%.
  • Comprehensive data analysis: We use industry standard software such as Bismark and a mature in-house pipeline for mapping, Differentially Methylated Region (DMR) analysis, functional analysis and data visualization.
  • Sample Requirements

     

    Sample Type
    Required amount
    Purity
    Genomic DNA
    ≥ 2.5 μg
    OD260/280=1.8-2.0

    Sequencing Parameter and Analysis

    Platform Type
    Illumina Novaseq 6000
    Read Length
    Paired-end 150
    Recommended Sequencing Depth
    ≥ 30× coverage for the species with reference genome
    Standard Data Analysis
  • Data quality control
  • mCs detection, methylation level calculation
  • Methylation level and frequency distribution
  • Differentially Methylated Site (DMS) detection
  • Differentially methylated regions (DMRs), Differentially Methylated Promoter (DMPs) detection and annotation
  • Function enrichment of DMR-associated genes and DMP-associated genes
  • Visualization of BS seq data
  • Comparative analysis (among samples)
  • Note: For detailed information, please refer to the Service Specifications and contact us for customized requests.

    Project Workflow

    Sampling & Sequencing Strategy:

    2.1. Samples:
    Four patient-matched CAF-NPF pairs (eight samples), and LNCaP and PrEC cell lines

    2.2. Library preparation:
    WGBS library and RNA-seq library

    2.3. Sequencing:
    Illumina HiSeq, PE100 and PE75

    2.4. Bioinformatics analysis:
    WGBS standard analysis and gene expression analysis

    Results & Conclusion:

    Functional DMRs define cell-type specificity between CAFs and NPFs across independent patients
    We selected 14 candidate genes with coordinated changes in methylation and expression and known roles in prostate cancer and/or the tumor microenvironment. All candidate regions showed a significant change in methylation (P < 0.05) in agreement with the WGBS data. Methylation levels at individual DMRs also discriminated between CAFs and NPFs, including HOXD8 with AUC = 1. We also found that 13 of 14 candidate genes were significantly differentially expressed in CAFs versus NPFs (P < 0.05). There was a strong negative correlation between expression and methylation for IGFBP2, ITGA11, ESR1, and EPHB6, all of which have DMRs downstream from their promoter. In contrast, there were strong positive correlations for PITX2, with a DMR in the last intron, and HOXD8 and EBF1, which have intergenic DMRs, suggesting a mechanistic link between methylation and expression at these loci. Collectively, our genome-wide and targeted validation, in independent patients, demonstrate that DE-DMRs are highly consistent between patients and define cell-type specificity between CAFs and NPFs (Firgure 1.).

     

    Figure 1. Consistent changes in DMRs associated with differentially expressed genes (DE-DMRs) between patients.


    Figure 1 Distribution of genome coverage


    Figure 2 Methylation level distribution in whole genome


    Figure 3 Heatmap analysis of gene functional region methylation levels


    Figure 4 An overview of methylation level distribution at functional genetic elements


    Figure 5 Circos plot for DMR condition in three contexts (CG, CHG, CHH)


    Figure 6 GO enrichment